[
  {
    "ts": null,
    "headline": "Canaccord Genuity Reiterates a Buy on Boston Scientific Corporation (BSX)",
    "summary": "​Boston Scientific Corporation (NYSE:BSX) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 23, William Plovanic from Canaccord Genuity reiterated a Buy rating on Boston Scientific Corporation (NYSE:BSX) with a price target of $132. ​The rating comes after the company, on October 22, released results for its fiscal […]",
    "url": "https://finnhub.io/api/news?id=ca0cd179af1b0d058104d13f5cd3c6f047b022f1e3de71341576ea15f2752410",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761751086,
      "headline": "Canaccord Genuity Reiterates a Buy on Boston Scientific Corporation (BSX)",
      "id": 137258702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "​Boston Scientific Corporation (NYSE:BSX) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 23, William Plovanic from Canaccord Genuity reiterated a Buy rating on Boston Scientific Corporation (NYSE:BSX) with a price target of $132. ​The rating comes after the company, on October 22, released results for its fiscal […]",
      "url": "https://finnhub.io/api/news?id=ca0cd179af1b0d058104d13f5cd3c6f047b022f1e3de71341576ea15f2752410"
    }
  },
  {
    "ts": null,
    "headline": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=55dcdda63ef7839215e2989abca9a3d6f3cff85c23fe68ba312598898d5f3731",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761745802,
      "headline": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
      "id": 137258703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=55dcdda63ef7839215e2989abca9a3d6f3cff85c23fe68ba312598898d5f3731"
    }
  },
  {
    "ts": null,
    "headline": "CVS Stock Falls Despite Q3 Earnings & Revenue Beat, '25 EPS View Up",
    "summary": "CVS shares slip even though Q3 earnings and revenues beat estimates, with the company boosting its 2025 EPS outlook.",
    "url": "https://finnhub.io/api/news?id=a828d0badf2a6cbaace9f89ddfb2e48d3cba3232fb268cb2e3d2ae2cbf869967",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761742800,
      "headline": "CVS Stock Falls Despite Q3 Earnings & Revenue Beat, '25 EPS View Up",
      "id": 137258704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "CVS shares slip even though Q3 earnings and revenues beat estimates, with the company boosting its 2025 EPS outlook.",
      "url": "https://finnhub.io/api/news?id=a828d0badf2a6cbaace9f89ddfb2e48d3cba3232fb268cb2e3d2ae2cbf869967"
    }
  },
  {
    "ts": null,
    "headline": "GE HealthCare Q3 Earnings and Revenues Beat Estimates, Net Margin Falls",
    "summary": "GE HealthCare's Q3 results show steady revenue growth as strong imaging and diagnostics offset tariff and margin pressures.",
    "url": "https://finnhub.io/api/news?id=e477bf4e71de0bd4a1bf5470fe118bb8c4e86d6a865ee6650705143313612b28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761742740,
      "headline": "GE HealthCare Q3 Earnings and Revenues Beat Estimates, Net Margin Falls",
      "id": 137258705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "GE HealthCare's Q3 results show steady revenue growth as strong imaging and diagnostics offset tariff and margin pressures.",
      "url": "https://finnhub.io/api/news?id=e477bf4e71de0bd4a1bf5470fe118bb8c4e86d6a865ee6650705143313612b28"
    }
  },
  {
    "ts": null,
    "headline": "ISRG vs BSX: Comparing Q3 Earnings, Growth Strategies and Prospects",
    "summary": "Both Intuitive Surgical and Boston Scientific posted strong Q3 results, but their sharply contrasting growth strategies make them very different investment stories.",
    "url": "https://finnhub.io/api/news?id=a799a3503a562aab81ab2a7f666783f0459a549632eb35777c835c4ade4ffbbf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761742680,
      "headline": "ISRG vs BSX: Comparing Q3 Earnings, Growth Strategies and Prospects",
      "id": 137258623,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Both Intuitive Surgical and Boston Scientific posted strong Q3 results, but their sharply contrasting growth strategies make them very different investment stories.",
      "url": "https://finnhub.io/api/news?id=a799a3503a562aab81ab2a7f666783f0459a549632eb35777c835c4ade4ffbbf"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Boston Scientific’s Q3 Earnings Call",
    "summary": "Boston Scientific’s third quarter saw a positive market reaction, reflecting operational execution across multiple business units. Management attributed the strong results to broad-based growth, especially in electrophysiology and the WATCHMAN left atrial appendage closure device, which CEO Michael Mahoney called “a gem for Boston Scientific.” The company also noted resilient demand in the U.S. and Asia Pacific, with double-digit growth in Japan and China. Mahoney emphasized that growth was driv",
    "url": "https://finnhub.io/api/news?id=cdcbed417823c96b2504debebb0515cc4c7f1807c8a526eb1d8c717550ab1f08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761716106,
      "headline": "5 Insightful Analyst Questions From Boston Scientific’s Q3 Earnings Call",
      "id": 137248079,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific’s third quarter saw a positive market reaction, reflecting operational execution across multiple business units. Management attributed the strong results to broad-based growth, especially in electrophysiology and the WATCHMAN left atrial appendage closure device, which CEO Michael Mahoney called “a gem for Boston Scientific.” The company also noted resilient demand in the U.S. and Asia Pacific, with double-digit growth in Japan and China. Mahoney emphasized that growth was driv",
      "url": "https://finnhub.io/api/news?id=cdcbed417823c96b2504debebb0515cc4c7f1807c8a526eb1d8c717550ab1f08"
    }
  },
  {
    "ts": null,
    "headline": "Is Boston Scientific’s Rally Justified After Another Year of Double Digit Gains?",
    "summary": "If you are trying to figure out what to do with Boston Scientific stock right now, you are not alone. It is one of those names that investors keep coming back to, especially after a remarkable run in recent years. Just think about it: the stock has climbed an impressive 19.4% in the past year and a staggering 187.3% over five years. Even more, the year-to-date gain of 13.0% and a steady 2.8% in the last 30 days suggest this momentum may have staying power. Behind these moves is a string of...",
    "url": "https://finnhub.io/api/news?id=9ed03ff3e618b1f6a3d776f270da386ce9318fb9cf64c6c1bfe357acc6ca3b14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761700316,
      "headline": "Is Boston Scientific’s Rally Justified After Another Year of Double Digit Gains?",
      "id": 137243706,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "If you are trying to figure out what to do with Boston Scientific stock right now, you are not alone. It is one of those names that investors keep coming back to, especially after a remarkable run in recent years. Just think about it: the stock has climbed an impressive 19.4% in the past year and a staggering 187.3% over five years. Even more, the year-to-date gain of 13.0% and a steady 2.8% in the last 30 days suggest this momentum may have staying power. Behind these moves is a string of...",
      "url": "https://finnhub.io/api/news?id=9ed03ff3e618b1f6a3d776f270da386ce9318fb9cf64c6c1bfe357acc6ca3b14"
    }
  }
]